Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities

IndustryPRwire -- Chinook Therapeutics announced that it has entered into a license agreement with Morehouse School of Medicine for certain patents supporting the development of therapeutics in kidney diseases that disproportionately affect people of West African descent and underserved communities.

Under the terms of the agreement, Chinook has been granted an exclusive, worldwide, sublicensable, royalty-bearing right and license under certain patents related to methods and compositions for the treatment and detection of kidney diseases, including HIV-associated nephropathy (HIVAN) and/or focal segmental glomerulosclerosis (FSGS) using endothelin-1 receptor antagonists, to develop and commercialize therapeutic products. Terms of the license agreement have not been disclosed.

Tom Frohlich, chief business officer of Chinook Commented “We are pleased to partner with Morehouse School of Medicine as we share a commitment to developing precision medicine therapies for kidney diseases with significant unmet medical needs, particularly in underserved populations, We intend to continue expanding the depth and breadth of our intellectual property portfolio as we advance our product pipeline and bring forward therapies that potentially improve health outcomes for all patients.”

James Lillard, Associate Dean for Research Affairs at Morehouse School of Medicine Commented “African Americans are three times more likely to require renal replacement therapy than their white counterparts. We are excited to partner with Chinook Therapeutics, This partnership is well-aligned with our shared vision of leading the creation and advancement of health equity.”

Related Posts

Subscribe Our Newsletter